Jazz Pharmaceuticals Sees FY24 Adj. EPS $18.15-$19.35 Vs $19.94 Est.; Revenue $4.00B-$4.20B Vs $4.088B Est.
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals projects its FY24 adjusted EPS to be between $18.15 and $19.35, which is below the estimated $19.94. The company also forecasts revenue to be in the range of $4.00B to $4.20B, closely aligning with the estimated $4.088B.

February 28, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jazz Pharmaceuticals projects lower-than-expected adjusted EPS for FY24 but forecasts revenue in line with estimates.
The projected adjusted EPS being lower than the estimated figure suggests potential disappointment among investors, likely leading to a short-term negative impact on JAZZ's stock price. However, the revenue forecast being in line with expectations may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100